• 1
    Frisch M,Biggar RJ,Engels EA,Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001; 285: 17361745.
  • 2
    Besson C,Goubar A,Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001; 98: 23392344.
  • 3
    Cote TR,Biggar RJ,Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer. 1997; 73: 645650.
  • 4
    Oriol A,Ribera JM,Esteve J, et al. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica. 2003; 88: 445453.
  • 5
    Wang ES,Straus DJ,Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicine, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer. 2003; 98: 11961205.
  • 6
    Cortes J,Thomas D,Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002; 94: 14921499.
  • 7
    Spina M,Gabarre J,Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002; 100: 19841988.
  • 8
    Galicier L,Fieschi C,Borie R, et al. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood. 2007; 110: 28462854.
  • 9
    Oriol A,Ribera JM,Brunet S,del Potro E,Abella E,Esteve J. Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica. 2005; 90: 990992.
  • 10
    Kaplan LD,Lee JY,Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005; 106: 15381543.
  • 11
    Hoelzer D,Hiddemann W,Baumann A, et al. High survival rate in adults Burkitt's lymphoma/leukemia and diffuse large B-cell lymphoma with mediastinal involvement. Blood. 2007; 110: 159a.
  • 12
    Hoelzer D,Ludwig WD,Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996; 87: 495508.
  • 13
    Harris NL,Jaffe ES,Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84: 13611392.
  • 14
    MittelmanF (ed). ISCN: An International System for Human Cytogenetic Nomenclature. Basel: Karger; 1995.
  • 15
    Carpenter CC,Cooper DA,Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000; 283: 381390.
  • 16
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 17
    Peto R,Pike MC,Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977; 35: 139.
  • 18
    Cox DR. Regression models and life tables. J Roy Stat Soc Ser B. 1972; 34: 187220.
  • 19
    Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood. 1992; 80: 820.
  • 20
    Beral V,Peterman T,Berkelman R,Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet. 1991; 337: 805809.
  • 21
    Lim ST,Karim R,Nathwani BN,Tulpule A,Espina B,Levine AM. AIDS-related Burkitt's lymphoma versus large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005; 23: 44304438.
  • 22
    Daniels I,Abulayha AM,Thomson BJ,Haynes AP. Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis. 2006; 11: 10131023.
  • 23
    Ribera JM,Oriol A,Morgades M, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma. Results of a phase II trial. Br J Haematol. 2008; 140: 411419.
  • 24
    Thomas DA,Faderl S,O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006; 106: 15691580.
  • 25
    Thomas DA,Kantarjian H,Cortes J, et al. Long-term outcome after hyper-CVAD and rituximab chemoimmunotherapy for Burkitt or Burkitt-like leukemia/lymphoma and mature B-cell acute lymphocytic leukemia. Blood. 2007; 118: 831a.